Results 71 to 80 of about 6,463,095 (311)

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer

Annals of Thoracic Medicine, 2015
Objectives: The effects of first-line chemotherapy on overall survival (OS) might be confounded by subsequent therapies in patients with small cell lung cancer (SCLC).
Hisao Imai, Keita Mori, Kazushige Wakuda, Akira Ono, Hiroaki Akamatsu, Takehito Shukuya, Tetsuhiko Taira, Hirotsugu Kenmotsu, Tateaki Naito, Kyoichi Kaira, Haruyasu Murakami, Masahiro Endo, Takashi Nakajima, Nobuyuki Yamamoto, Toshiaki Takahashi   +14 more
doaj   +1 more source

Progression-free survival among patients with metastatic breast cancer according to CTC level.

, 2019
Progression-free survival among patients with metastatic breast cancer according to CTC level.
Yoon-Sim Yap (7429955), Elaine Hsuen Lim (6310085), Yong Wei Chua (7429961), Guofeng Guan (1835188), Ali Asgar S. Bhagat (7429982), John Heng-Chi Lim (7429973), Rebecca Dent (5313869), Angela Tan (7429976), Guek Eng Lee (7429967), Andrew Wu (90389), Darren Wan-Teck Lim (7429985), Raymond Chee Hui Ng (7429970), Man Chun Leong (7429958), Kiley Wei Jen Loh (7429964), Yi Fang Lee (7429979), Garima Singh (113127)   +15 more
core   +1 more source

Progression free survival and overall survival in all patients.

, 2022
Progression free survival and overall survival in all patients.
Youngil Koh (3196416), Ja Min Byun (3269547), Sung-Soo Yoon (1522603), Junshik Hong (3337527), Inho Kim (271420), Sock-Won Yoon (12008851), Hyunkyung Park (842078), Dong-Yeop Shin (3269553)   +7 more
core   +1 more source

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source

Chromothripsis and progression-free survival in metastatic colorectal cancer

Molecular and Clinical Oncology, 2017
Metastatic dissemination of the primary tumor is the major cause of death in colorectal cancer (CRC) patients. Multiple chromosomal breaks and chromothripsis, a phenomenon involving multiple chromosomal fragmentations occurring in a single catastrophic event, are associated with cancer genesis, progression and developing of metastases.
Skuja, Elina, Kalniete, Dagnija, Nakazawa-Miklasevica, Miki, Daneberga, Zanda, Abolins, Arnis, Purkalne, Gunta, Miklasevics, Edvins   +6 more
openaire   +3 more sources

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study

BMC Cancer, 2020
Background The purpose of this study was to assess the efficacy and safety of cisplatin-based chemotherapy with or without bevacizumab (BEV) in Chinese women with advanced cervical cancer (ACC).
Xiaoli He, Jun Liu, Li Xiao, Mingdong Zhao, Tingting Su, Tiejian Liu, Guowei Han, Yue Wang   +7 more
doaj   +1 more source

Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study

BMC Cancer, 2023
Purpose The aim of the present study was to assess the efficacy and safety of transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab (hereafter, TACE-Atez/Bev) in the treatment of advanced hepatocellular carcinoma (HCC ...
Fei Cao, Changsheng Shi, Guofu Zhang, Jun Luo, Jiaping Zheng, Weiyuan Hao   +5 more
doaj   +1 more source

The microbiome in human skin aging

FEBS Letters, EarlyView.
Age‐related skin changes encompass the well‐known visible phenotypic alterations, together with microbiome dysbiosis and a series of molecular aging hallmarks. These hallmarks characterize not only a fully stablished aged phenotype but also the skin aging process itself.
Manuel Huerta Arana, Cornelia Wiegand, Omid Omrani, Mario Fabri   +3 more
wiley   +1 more source

Progression-free survival in patients with stage IV colorectal cancer.

, 2019
The median progression-free survival in stage IV cases was significantly shorter in Group Y. Group Y, patients ≤50 years; Group O, patients >50 years (Group Y (8 months) vs. Group O (14 months); P = 0.002).
Young Bae Kim (847792), Seung Yeop Oh (6853007), Chinock Cheong (6853004), Kwang Wook Suh (6853010)   +3 more
core   +1 more source